MAZE

Maze Therapeutics Inc

26.21

Sep 04 • 3:59 PM ET +0.34 (1.31%)

26.21

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: KYMR BMRN CRNX RYTM INCY KRYS VKTX AXSM MDGL NBIX

| Held by: VTI XPH VXF VTWO TCAF SCHA SBIO VHT FESM VTWG

Scroll to Statements

Index	RUT
Market Cap	1.46B
Enterprise Value	1.11B
Income	-133.59M
Sales	20.00M
Book/sh	8.16
Cash/sh	7.40
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	141
IPO	Jan 31, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	72.80
P/B	3.21
P/C	3.54
P/FCF	-
EV/EBITDA	-
EV/Sales	55.26
Quick Ratio	18.31
Current Ratio	18.31
Debt/Eq	0.13
LT Debt/Eq	0.12
Option/Short	Yes / Yes

EPS (ttm)	-2.53
EPS next Y	-3.21
EPS next Q	-0.76
EPS this Y	9.43%
EPS next Y	-16.18%
EPS next 5Y	-5.40%
EPS past 3/5Y	-0.41% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-50.45%
Sales Y/Y TTM	700.00%
EPS Q/Q	1.29%
Sales Q/Q	-
Earnings	Aug 11 AMC
EPS/Sales Surpr.	-5.95% -100.00%

Insider Own	38.10%
Insider Trans	-1.86%
Inst Own	69.43%
Inst Trans	11.86%
ROA	-31.99%
ROE	-37.35%
ROIC	-26.26%
Gross Margin	90.47%
Oper. Margin	-728.06%
Profit Margin	-667.95%
SMA20	-6.34%
SMA50	-8.47%
SMA200	-23.39%
Trades

Shs Outstand	55.50M
Shs Float	34.39M
Short Float	17.41%
Short Ratio	10.92
Short Interest	5.99M
52W High	53.65 -51.15%
52W Low	14.16 85.13%
Volatility	4.51% 4.78%
ATR (14)	1.36
RSI (14)	39.77
Beta	2.17
Rel Volume	0.50
Avg Volume	548.34K
Volume	273,269

Perf Week	-4.48%
Perf Month	-8.13%
Perf Quarter	7.99%
Perf Half Y	-41.53%
Perf YTD	-36.74%
Perf Year	74.27%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	62.55
Prev Close	25.87
Price	26.21
Change %	1.31%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-18-26	Initiated	Truist	Buy	$68
Mar-10-26	Initiated	Mizuho	Outperform	$97
Dec-04-25	Initiated	Wells Fargo	Overweight	$55
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy	$30
Jul-23-25	Initiated	H.C. Wainwright	Buy	$34
Jul-08-25	Initiated	Wedbush	Outperform	$17

Sep-02-26 07:00AM	Maze Therapeutics to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Aug-13-26 04:42PM	Maze Therapeutics Announces Appointments to Its Board of Directors (GlobeNewswire)
Aug-11-26 04:01PM	Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
May-27-26 07:03AM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-12-26 04:01PM	Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights (GlobeNewswire)
12:09AM	Loading…
Apr-22-26 12:09AM	Maze Therapeutics Announces $150 Million Registered Offering (GlobeNewswire)
Apr-01-26 09:46AM	Disney upgraded, Nike downgraded: Wall Street's top analyst calls (The Fly)
Mar-31-26 08:06PM	After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Maze Therapeutics, Inc. (MAZE) (Quartz)
Mar-25-26 02:35PM	Maze set to target Vertex as kidney disease drug succeeds in Phase II trial (Clinical Trials Arena) -35.24%
11:25AM	Maze tumbles on positive data for kidney disease drug (BioPharma Dive)
11:25AM	Maze tumbles despite positive data for kidney disease drug (BioPharma Dive)
09:53AM	Why Maze Therapeutics Plunged 20%-Plus Despite 'Overwhelming Positive' Data (Investor's Business Daily)
07:00AM	Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights (GlobeNewswire)
07:00AM	Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease (GlobeNewswire)
Mar-18-26 09:34AM	Block upgraded, Starbucks downgraded: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
Feb-25-26 07:00AM	Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-14-26 04:06AM	Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit (MarketBeat)
Feb-04-26 07:00AM	Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 (GlobeNewswire)
Jan-05-26 07:00AM	Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-06-25 04:01PM	Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
07:00AM	Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week (GlobeNewswire)
Nov-04-25 07:00AM	Maze Therapeutics to Participate in Four Upcoming Investor Conferences (GlobeNewswire)
Oct-28-25 04:43PM	Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease (CNBC TV)
Oct-06-25 07:00AM	Maze Therapeutics Appoints Industry Veteran Herve Hoppenot as Chairman of the Board of Directors (GlobeNewswire)
Sep-19-25 04:02PM	Maze Therapeutics, Inc. (MAZE): A Bull Case Theory (Insider Monkey)
Sep-17-25 06:22PM	Biotech Breakouts: 3 Stocks With Massive Upside Potential (MarketBeat)
Sep-12-25 07:45AM	Maze reports positive results from Phase I trial of PKU and CKD treatment (Clinical Trials Arena) -6.07%
06:45AM	Takeda poaches top Lilly exec; Maze soars on early PKU drug data (BioPharma Dive)
Sep-11-25 09:29AM	Why Maze Therapeutics, Up 51%, Was Shocked By Its Own Test Results (Investor's Business Daily) +54.81%
07:35AM	Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement (GlobeNewswire)
07:30AM	Loading…
07:30AM	Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) (GlobeNewswire)
Sep-02-25 07:00AM	Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer (GlobeNewswire) +5.73%
Aug-12-25 04:01PM	Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights (GlobeNewswire)
Jul-31-25 07:46AM	Venture firm Frazier closes $1.3B fund for early-stage biotech investing (BioPharma Dive)
Jul-10-25 04:05PM	Maze Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
May-29-25 07:30AM	Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference (GlobeNewswire) +6.01%
May-14-25 04:01PM	Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones (GlobeNewswire) -8.11%
May-13-25 07:30AM	Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference (GlobeNewswire)
Mar-31-25 07:30AM	Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights (GlobeNewswire)
Mar-26-25 05:02PM	Maze Therapeutics: Interesting Science But IPO-Related And Other Risks Exist (SeekingAlpha) -7.48%
Feb-25-25 04:11PM	Maze Therapeutics receives positive ratings following recent IPO (Investing.com) +10.69%
Feb-10-25 07:09AM	Maze Therapeutics doses first subject in Phase II AKD treatment trial (Clinical Trials Arena)
Feb-07-25 08:00AM	Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease (GlobeNewswire)
Jan-30-25 08:13PM	Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs (Bloomberg)
07:30PM	Maze Therapeutics Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)
02:57PM	Metsera, Maze secure combined $415 million in IPOs (BioPharma Dive)

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

M.P.H.Dr. Jason V. Coloma M.B.A.

CFO & Principal Accounting OfficerMr. Misbah Tahir CPA

Ph.D.Dr. Harold S. Bernstein M.D.

Vice President of R&D Infrastructure and OperationsMr. Vipin Vijayakumar

General Counsel & Corporate SecretaryMs. Courtney J. Phillips J.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HAROLD BERNSTEIN	Officer	Sep 04 '26	Proposed Sale	25.87	9,705	251,068		Sep 04 04:34 PM
Courtney Phillips	GC and Corp. Secretary	Sep 02 '26	Sale	26.47	1,981	52,432	9,019	Sep 04 04:27 PM
Courtney Phillips	GC and Corp. Secretary	Sep 03 '26	Sale	26.01	2,012	52,334	7,007	Sep 04 04:27 PM
Dandekar Atul	CSBO	Sep 02 '26	Sale	26.47	3,191	84,457	35,559	Sep 04 04:25 PM
Dandekar Atul	CSBO	Sep 03 '26	Sale	26.01	3,243	84,354	32,316	Sep 04 04:25 PM
Coloma Jason V	Chief Executive Officer	Sep 02 '26	Sale	26.47	11,227	297,148	38,773	Sep 04 04:24 PM
Coloma Jason V	Chief Executive Officer	Sep 03 '26	Sale	26.01	11,411	296,807	27,362	Sep 04 04:24 PM
Bernstein Harold	President, R&D & CMO	Sep 02 '26	Sale	26.47	5,106	135,142	14,894	Sep 04 04:22 PM
Bernstein Harold	President, R&D & CMO	Sep 03 '26	Sale	26.01	5,189	134,969	9,705	Sep 04 04:22 PM
Courtney Phillips	GC and Corp. Secretary	Sep 01 '26	Option Exercise	0.00	11,000	0	11,000	Sep 03 04:31 PM
Dandekar Atul	CSBO	Sep 01 '26	Option Exercise	0.00	12,500	0	38,750	Sep 03 04:29 PM
Coloma Jason V	Chief Executive Officer	Sep 01 '26	Option Exercise	0.00	50,000	0	50,000	Sep 03 04:27 PM
Coloma Jason V	Chief Executive Officer	Sep 01 '26	Sale	26.29	34,501	906,999	18,151	Sep 03 04:27 PM
Bernstein Harold	President, R&D & CMO	Sep 01 '26	Option Exercise	4.65	36,141	168,189	20,000	Sep 03 04:24 PM
Bernstein Harold	President, R&D & CMO	Sep 01 '26	Sale	26.36	16,141	425,512	0	Sep 03 04:24 PM
Courtney Phillips	Officer	Sep 02 '26	Proposed Sale	26.54	4,144	110,000		Sep 02 07:05 PM
Atul Dandekar	Officer	Sep 02 '26	Proposed Sale	26.53	6,679	177,200		Sep 02 07:03 PM
Jason V Coloma	Officer	Sep 02 '26	Proposed Sale	26.53	23,497	623,400		Sep 02 07:02 PM
Harold Bernstein	Officer	Sep 02 '26	Proposed Sale	26.53	10,685	283,500		Sep 02 07:00 PM
Coloma Jason V	Officer	Sep 01 '26	Proposed Sale	26.32	34,501	908,066		Sep 01 04:03 PM
Dandekar Atul	CSBO	Aug 28 '26	Option Exercise	10.42	7,500	78,150	33,750	Aug 31 06:32 PM
Dandekar Atul	CSBO	Aug 28 '26	Sale	27.58	7,500	206,824	26,250	Aug 31 06:32 PM
Bernstein Harold	President, R&D & CMO	Aug 13 '26	Option Exercise	10.42	16,142	168,200	16,142	Aug 14 04:54 PM
Bernstein Harold	President, R&D & CMO	Aug 13 '26	Sale	27.61	16,142	445,621	0	Aug 14 04:54 PM
Coloma Jason V	Chief Executive Officer	Aug 03 '26	Sale	26.73	34,501	922,315	20,744	Aug 05 04:08 PM
Coloma Jason V	Officer	Aug 03 '26	Proposed Sale	26.74	34,501	922,557		Aug 03 04:08 PM
Dandekar Atul	CSBO	Jul 29 '26	Option Exercise	10.42	7,500	78,150	33,750	Jul 31 04:15 PM
Dandekar Atul	CSBO	Jul 29 '26	Sale	27.34	7,500	205,031	26,250	Jul 31 04:15 PM
ATUL DANDEKAR	Officer	Jul 29 '26	Proposed Sale	27.88	22,500	627,300		Jul 29 04:18 PM
Bernstein Harold	President, R&D & CMO	Jul 01 '26	Option Exercise	10.42	14,609	152,226	14,609	Jul 02 04:29 PM
Bernstein Harold	President, R&D & CMO	Jul 01 '26	Sale	29.90	14,609	436,864	0	Jul 02 04:29 PM
Coloma Jason V	Chief Executive Officer	Jul 01 '26	Sale	29.98	34,501	1,034,253	23,337	Jul 02 04:28 PM
HAROLD BERNSTEIN	Officer	Jul 01 '26	Proposed Sale	29.84	46,892	1,399,257		Jul 01 05:00 PM
Dandekar Atul	CSBO	Jun 29 '26	Option Exercise	10.42	7,500	78,150	33,750	Jul 01 04:17 PM
Dandekar Atul	CSBO	Jun 29 '26	Sale	28.02	7,500	210,150	26,250	Jul 01 04:17 PM
Coloma Jason V	Officer	Jul 01 '26	Proposed Sale	29.98	34,501	1,034,254		Jul 01 04:04 PM
Coloma Jason V	Chief Executive Officer	Jun 23 '26	Sale	26.05	23,865	621,674	319,079	Jun 24 04:14 PM
Coloma Jason V	Chief Executive Officer	Jun 22 '26	Sale	26.00	3,993	103,821	25,930	Jun 24 04:14 PM
Coloma Jason V	Chief Executive Officer	Jun 01 '26	Sale	26.20	6,643	174,048	27,970	Jun 03 05:04 PM
Bernstein Harold	President, R&D & CMO	Jun 01 '26	Option Exercise	10.42	14,853	154,768	14,853	Jun 03 05:01 PM
Bernstein Harold	President, R&D & CMO	Jun 01 '26	Sale	25.66	14,853	381,112	0	Jun 03 05:01 PM
Dandekar Atul	CSBO	May 29 '26	Option Exercise	10.42	7,500	78,150	32,308	Jun 02 04:12 PM
Dandekar Atul	CSBO	May 29 '26	Sale	26.34	7,500	197,554	24,808	Jun 02 04:12 PM
Coloma Jason V	Officer	Jun 01 '26	Proposed Sale	26.32	34,501	908,066		Jun 01 04:16 PM
Coloma Jason V	Chief Executive Officer	May 26 '26	Sale	26.02	25,582	665,516	350,987	May 27 04:16 PM
Coloma Jason V	Chief Executive Officer	May 22 '26	Sale	26.00	6,982	181,532	28,523	May 27 04:16 PM
Coloma Jason V	Chief Executive Officer	May 15 '26	Sale	26.00	1,938	50,388	31,001	May 18 05:07 PM
Bernstein Harold	President, R&D & CMO	May 14 '26	Option Exercise	10.42	15,000	156,300	15,000	May 18 05:03 PM
Bernstein Harold	President, R&D & CMO	May 14 '26	Sale	26.22	15,000	393,354	0	May 18 05:03 PM
Coloma Jason V	Officer	May 15 '26	Proposed Sale	25.95	34,502	895,327		May 15 05:09 PM
Dandekar Atul	CSBO	May 04 '26	Option Exercise	10.42	14,305	149,058	24,808	May 06 04:15 PM
Dandekar Atul	CSBO	Apr 29 '26	Option Exercise	10.42	7,500	78,150	18,003	May 01 04:18 PM
Dandekar Atul	CSBO	Apr 29 '26	Sale	25.37	7,500	190,299	10,503	May 01 04:18 PM
Bernstein Harold	President, R&D & CMO	Apr 01 '26	Option Exercise	10.42	15,000	156,300	15,000	Apr 02 04:08 PM
Bernstein Harold	President, R&D & CMO	Apr 01 '26	Sale	29.46	15,000	441,904	0	Apr 02 04:08 PM
Bachrodt Amy	SVP, Finance	Apr 01 '26	Option Exercise	10.42	2,500	26,050	15,465	Apr 02 04:06 PM
Bachrodt Amy	SVP, Finance	Apr 01 '26	Sale	29.44	2,500	73,611	12,965	Apr 02 04:06 PM
Dandekar Atul	CSBO	Mar 30 '26	Option Exercise	10.42	7,500	78,150	18,003	Apr 01 04:12 PM
Dandekar Atul	CSBO	Mar 30 '26	Sale	29.34	7,500	220,019	10,503	Apr 01 04:12 PM
ATUL DANDEKAR	Officer	Mar 30 '26	Proposed Sale	30.38	30,000	911,400		Mar 30 05:31 PM
Bernstein Harold	President, R&D & CMO	Mar 20 '26	Option Exercise	10.42	15,000	156,300	15,000	Mar 20 06:50 PM
Bernstein Harold	President, R&D & CMO	Mar 20 '26	Sale	49.10	15,000	736,439	0	Mar 20 06:50 PM
Bernstein Harold	President, R&D & CMO	Mar 10 '26	Option Exercise	10.42	30,000	312,600	30,000	Mar 12 04:51 PM
Bernstein Harold	President, R&D & CMO	Mar 10 '26	Sale	50.45	30,000	1,513,560	0	Mar 12 04:51 PM
HAROLD BERNSTEIN	Officer	Mar 10 '26	Proposed Sale	45.06	74,853	3,372,876		Mar 10 04:33 PM
Bernstein Harold	President, R&D & CMO	Feb 02 '26	Option Exercise	10.42	15,000	156,300	15,000	Feb 04 04:25 PM
Bernstein Harold	President, R&D & CMO	Feb 02 '26	Sale	46.02	15,000	690,334	0	Feb 04 04:25 PM
Bachrodt Amy	SVP, Finance	Feb 02 '26	Option Exercise	10.42	5,000	52,100	17,965	Feb 04 04:23 PM
Bachrodt Amy	SVP, Finance	Feb 02 '26	Sale	46.04	5,000	230,219	12,965	Feb 04 04:23 PM
Dandekar Atul	CSBO	Jan 29 '26	Option Exercise	10.42	7,500	78,150	18,003	Feb 02 04:21 PM
Dandekar Atul	CSBO	Jan 29 '26	Sale	44.27	7,500	331,990	10,503	Feb 02 04:21 PM
Bachrodt Amy	SVP, Finance	Jan 22 '26	Option Exercise	10.42	5,000	52,100	17,965	Jan 26 04:10 PM
Bachrodt Amy	SVP, Finance	Jan 22 '26	Sale	45.52	5,000	227,612	12,965	Jan 26 04:10 PM
SEKAR KATHIRESAN	Former Director	Jan 16 '26	Proposed Sale	40.67	29,772	1,210,937		Jan 16 04:28 PM
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Option Exercise	10.42	25,156	262,126	25,156	Jan 09 04:51 PM
Bernstein Harold	President, R&D & CMO	Jan 07 '26	Sale	40.20	25,156	1,011,299	0	Jan 09 04:51 PM
Sohn Catherine A.	Director	Jan 07 '26	Option Exercise	10.42	26,920	280,506	26,920	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Option Exercise	10.42	2,493	25,977	2,493	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 07 '26	Sale	39.11	26,920	1,052,785	0	Jan 08 04:30 PM
Sohn Catherine A.	Director	Jan 06 '26	Sale	38.62	2,493	96,270	0	Jan 08 04:30 PM
CATHERINE SOHN	Director	Jan 07 '26	Proposed Sale	39.11	26,920	1,052,785		Jan 07 04:00 PM
CATHERINE SOHN	Director	Jan 06 '26	Proposed Sale	38.62	2,493	96,270		Jan 06 04:36 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Option Exercise	10.42	4,432	46,181	4,432	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Option Exercise	10.42	412	4,293	412	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 02 '26	Sale	40.43	4,432	179,188	0	Jan 06 04:31 PM
Bernstein Harold	President, R&D & CMO	Jan 05 '26	Sale	40.00	412	16,480	0	Jan 06 04:31 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Option Exercise	10.42	5,000	52,100	17,965	Jan 06 04:30 PM
Bachrodt Amy	SVP, Finance	Jan 02 '26	Sale	39.15	5,000	195,754	12,965	Jan 06 04:30 PM
Dandekar Atul	CSBO	Dec 29 '25	Option Exercise	10.42	72,400	754,408	82,903	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Option Exercise	10.42	100	1,042	10,603	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 29 '25	Sale	40.56	72,400	2,936,763	10,503	Dec 31 04:24 PM
Dandekar Atul	CSBO	Dec 30 '25	Sale	40.36	100	4,036	10,503	Dec 31 04:24 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Option Exercise	10.42	45,000	468,900	45,000	Dec 31 04:22 PM
Bernstein Harold	President, R&D & CMO	Dec 29 '25	Sale	40.56	45,000	1,825,355	0	Dec 31 04:22 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Option Exercise	10.42	10,000	104,200	22,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Option Exercise	10.42	5,000	52,100	17,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 29 '25	Sale	40.58	10,000	405,766	12,965	Dec 31 04:20 PM
Bachrodt Amy	SVP, Finance	Dec 30 '25	Sale	40.08	5,000	200,407	12,965	Dec 31 04:20 PM
HAROLD BERNSTEIN	Officer	Dec 29 '25	Proposed Sale	42.10	105,000	4,420,500		Dec 29 04:28 PM
ATUL P DANDEKAR	Officer	Dec 29 '25	Proposed Sale	42.10	87,500	3,683,750		Dec 29 04:25 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MAZE

Maze Therapeutics Inc

Upgrade your Finviz experience